CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor

Acquisition of U.K. Medical supports expansion of Procedural Solutions business in Europe

News provided by

Jun 07, 2012, 08:30 ET

SAN DIEGO, June 7, 2012 /PRNewswire/ -- CareFusion today announced the acquisition of U.K. Medical Limited, a leading distributor of medical products to the National Health Service (NHS) and private health care sector in the United Kingdom. Terms of the deal were not disclosed.

The acquisition, the company's fifth, is part of CareFusion's strategy to expand globally by investing to build scale, infrastructure and local capabilities in key markets. U.K. Medical has strong customer relationships and clinical marketing expertise with specialized medical technologies including products used in interventional radiology and for surgical and vascular access in acute-care hospitals.

"The acquisition further strengthens CareFusion's presence in the United Kingdom, where we have built leadership positions in infusion therapy and infection prevention," said Gordon LaFortune, executive vice president of International Commercial Operations for CareFusion. "We believe this acquisition will help us expand our long-standing partnership with U.K. Medical and better leverage the company's clinical expertise to continue to grow our Procedural Solutions business in the United Kingdom and beyond."

U.K. Medical primarily serves the National Health Service and focuses on distribution of clinically differentiated interventional and implantable single-use medical products for biopsy, cardiac, drainage, obstetrics and gynecology, non-vascular stenting, surgery and vertebroplasty.

The company served as the sole U.K. distributor of CareFusion's Interventional Technologies portfolio, including soft-tissue and bone marrow biopsy needles, the AVAmax® Advanced Vertebral Augmentation System and the PleurX® Peritoneal Catheter Drainage System, which the National Institute for Health and Clinical Excellence (NICE) recently supported through published guidance for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. Over the past three years, U.K. Medical has contributed to a nearly 50 percent growth of CareFusion's Interventional Technologies portfolio in the United Kingdom. The company also markets medical products for approximately 10 additional suppliers.

"For more than 30 years, we have served the NHS and private medical sector with high-quality, high-technology medical products to help improve patient care pathways," said Jim Mackenzie, chairman of U.K. Medical. "We look forward to continuing our track record of growth and innovation with CareFusion."

U.K. Medical has nearly 40 employees and is headquartered in Sheffield, United Kingdom. CareFusion currently employs approximately 350 people in the United Kingdom.

About CareFusion
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® skin prep products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

SOURCE CareFusion